Company intelligence / Profile preview

Albert Labs

Burnaby, British Columbia, Canadaalbertlabs.com ↗

Ownership: Private
Development stage: Commercial

Overview

Albert Labs is developing KRN‑101, a standardized mycelium-derived pharmaceutical candidate targeting cancer-related anxiety/distress. The company has established GMP production capabilities and is pursuing regulatory approval via Real World Evidence studies. Other pipeline programs target substance use disorders, chronic pain, and neurodegenerative diseases but remain at an early stage.

Therapeutic areas: PsychiatryNeurology
Modalities: Natural extract (mycelium-based therapy)Small moleculeBiologic
Industry: Biotech

Partnerships

Chrystal Capital Partners advised on European listing

Beyond the preview

Go deeper on Albert Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albert Labs.